Figure 12.
Blood vessel grafts for clinic trials
(A) An 80-year-old female patient with a history of glomerulonephritis and coronary artery disease underwent the implantation of an allogeneic tissue-engineered vascular graft for the first time, with post-transplant Doppler ultrasound showing stable blood flow, normal blood indices, and negative panel reactive antibody tests, indicating successful arteriovenous anastomosis. Copyright 2014, Mosby, Reproduced with permission.193
(B) A 29-year-old Ukrainian male combat casualty sustained a blast injury to the left leg, with pre-operative computed tomography (CT) scans revealing shrapnel in the vascular bundle adjacent to the inguinal ligament; subsequent repair of the left common femoral artery using HAVs was uncomplicated by infection during follow-up. Copyright 2023, Elsevier, Reproduced with permission.222
(C) Patients with end-stage renal disease successfully underwent the implantation of HAVs as an arteriovenous conduit, with postoperative monitoring showing no significant changes in vascular performance, and the HAVs proved suitable for repeated cannulation for hemodialysis. Copyright 2019, American Association for the Advancement of Science, Reproduced with permission.223
(D) A case study of six-year hemodialysis using a HAV demonstrates that despite a long-term puncture and catheter dilation, vascular ultrasound, and immunofluorescence staining indicate the preservation of structural and functional integrity of the HAVs. Copyright 2022, Elsevier, Reproduced with permission.224